Aim: The aim of this meta‐analysis of randomized clinical trials (RCT) was to assess whether
pioglitazone is also associated with increased cardiovascular risk, as recently reported for …

A recent meta-analysis suggested that the use of rosiglitazone increases the risk of
myocardial infarction (MI) in patients with type 2 diabetes mellitus. It is unclear whether this …

Background and aims Pioglitazone targets multiple pathogenic pathways involved in the
development of cardiovascular diseases (CVD). The aim of this systematic review and meta …

The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome
proliferator-activated receptor-γ, and decreases metabolic and vascular insulin resistance …

Objective To compare the risk of acute myocardial infarction, heart failure, and death in
patients with type 2 diabetes treated with rosiglitazone and pioglitazone. Design …

To the Editor: The meta-analysis by Nissen and Wolski includes two large trials with primary
end points that did not include cardiovascular events. In the Diabetes Reduction …

Objective: To review the evidence surrounding rosiglitazone and ischemic cardiovascular
risk and discuss the Food and Drug Administration (FDA) decision to revise safety …

Objectives Describe and compare the risk of cardiovascular and non-cardiovascular
mortality in patients whose antidiabetic therapy is modified to include pioglitazone compared …

Background A recent and provocative meta-analysis, based on few outcome events,
suggested that rosiglitazone increased cardiovascular mortality and myocardial infarction …

ContextPioglitazone is widely used for glycemic control in patients with type 2 diabetes
mellitus, but evidence is mixed regarding the influence of medications of this class on …